Human papillomavirus vaccines in Picardy,France: Coverage and correlation with socioeconomic factors

BackgroundIn France, the human papillomavirus vaccine is routinely recommended for 14-year-old females and a “catch-up” vaccination should be offered to female adolescents who are between 15 and 23 years of age. Currently, few studies are available on the coverage rates in France. The aim of this study was to evaluate the coverage of the human papillomavirus vaccine and compliance with the vaccination scheme in Picardy, between 2009 and 2010, and to analyze the socioeconomic factors possibly influencing this coverage.MethodsWe selected a female population that was affiliated with the national health insurance organization, living in the Picardy region of France, and aged between 14 and 23 years on 31st December 2010.ResultsThe coverage rate in the study population with at least one dose of vaccine was 16.8%. A complete vaccination scheme (three doses) was observed in less than 38.9% of them, so only 6.5% of this population had received the complete vaccination. Higher rates of coverage and compliance were observed in girls 14 years of age (65.5%) and if the prescriber was a gynecologist or pediatrician (respectively, 44.7% and 48.1%). There is a negative correlation between coverage and compliance and the percentage of single-parent families and immigrant families by canton area of Picardy. The economic cost of an inappropriate scheme was 1.3 million euros for Picardy in 2009.ConclusionCoverage and compliance rates of human papillomavirus vaccines in Picardy appear to be low. This study suggests that health authorities in Picardy should provide communication and action campaigns to improve these results.     

Lyme borreliosis and other tick-borne diseases. Guidelines from the French Scientific Societies (I): prevention,epidemiology, diagnosis

Lyme borreliosis is transmitted en France by the tick Ixodes ricinus, endemic in metropolitan France. In the absence of vaccine licensed for use in humans, primary prevention mostly relies on mechanical protection (clothes covering most parts of the body) that may be completed by chemical protection (repulsives). Secondary prevention relies on early detection of ticks after exposure, and mechanical extraction. There is currently no situation in France when prophylactic antibiotics would be recommended. The incidence of Lyme borreliosis in France, estimated through a network of general practitioners (réseau Sentinelles), and nationwide coding system for hospital stays, has not significantly changed between 2009 and 2017, with a mean incidence estimated at 53 cases/100,000 inhabitants/year, leading to 1.3 hospital admission/100,000 inhabitants/year. Other tick-borne diseases are much more seldom in France: tick-borne encephalitis (around 20 cases/year), spotted-fever rickettsiosis (primarily mediterranean spotted fever, around 10 cases/year), tularemia (50–100 cases/year, of which 20% are transmitted by ticks), human granulocytic anaplasmosis (< 10 cases/year), and babesiosis (< 5 cases/year). The main circumstances of diagnosis for Lyme borreliosis are cutaneous manifestations (primarily erythema migrans, much more rarely borrelial lymphocytoma and atrophic chronic acrodermatitis), neurological (< 15% of cases, mostly meningoradiculitis and cranial nerve palsy, especially facial nerve) and rheumatologic (mostly knee monoarthritis, with recurrences). Cardiac and ophtalmologic manifestations are very rarely encountered.     

Lyme borreliosis and other tick-borne diseases. Guidelines from the French scientific societies (II). Biological diagnosis,treatment, persistent symptoms after documented or suspected Lyme borreliosis

The serodiagnosis of Lyme borreliosis is based on a two-tier strategy: a screening test using an immunoenzymatic technique (ELISA), followed if positive by a confirmatory test with a western blot technique for its better specificity. Lyme serology has poor sensitivity (30–40%) for erythema migrans and should not be performed. The seroconversion occurs after approximately 6 weeks, with IgG detection (sensitivity and specificity both > 90%). Serological follow-up is not recommended as therapeutic success is defined by clinical criteria only. For neuroborreliosis, it is recommended to simultaneously perform ELISA tests in samples of blood and cerebrospinal fluid to test for intrathecal synthesis of Lyme antibodies. Given the continuum between early localized and disseminated borreliosis, and the efficacy of doxycycline for the treatment of neuroborreliosis, doxycycline is preferred as the first-line regimen of erythema migrans (duration, 14 days; alternative: amoxicillin) and neuroborreliosis (duration, 14 days if early, 21 days if late; alternative: ceftriaxone). Treatment of articular manifestations of Lyme borreliosis is based on doxycycline, ceftriaxone, or amoxicillin for 28 days. Patients with persistent symptoms after appropriate treatment of Lyme borreliosis should not be prescribed repeated or prolonged antibacterial treatment. Some patients present with persistent and pleomorphic symptoms after documented or suspected Lyme borreliosis. Another condition is eventually diagnosed in 80% of them.